LYEL

Lyell Immunopharma, Inc.

Insider Trades

NameValueActionPriceCurrent Price
Seely LynnDirector, Officer: President And CEO
$106k175k shares
BuyMar 14, 2025
$0.6068
--
Newton Charles W.Chief Financial Officer
$112k200k shares
BuyMar 17, 2025
$0.5581
--
Klausner RichardDirector
$95k158k shares
BuyMar 14, 2025
$0.6009
--
Ramachandra SumantDirector
$115k200k shares
BuyMar 21, 2025
$0.5761
--
Brawley Otis WDirector
$20k35.6k shares
BuyMar 31, 2025
$0.56
--
Newton Charles W.Chief Financial Officer
$1.4k136 shares
SellAug 12, 2025
$10.34
--

News

seekingalpha.comLyell Immunopharma: Undervalued Ahead Of A Major CAR-T Inflectionseekingalpha.comJun 13globenewswire.comLyell Immunopharma Presents Updated Safety Data and Translational Insights for Rondecabtagene Autoleucel (Ronde-Cel) in Patients with Large B-Cell Lymphoma at European Hematology Association 2026 Congressglobenewswire.comJun 12seekingalpha.comLyell Immunopharma, Inc. (LYEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcriptseekingalpha.comJun 10benzinga.comLyell Immunopharma Issues Colorectal Cancer Drug Safety Updatebenzinga.comJun 8globenewswire.comLyell Immunopharma Provides Update on Safety Profile of LYL273 in Relapsed or Refractory Metastatic Colorectal Cancer and Amends Phase 1 Trial to Phase 1/2 Expansionglobenewswire.comJun 8